ARMO BioSciences fetches $50 mln Series C
ARMO BioSciences has closed $50 million in Series C funding. The investors included Kleiner Perkins Caufield & Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, Industrial Investors Group and certain private investment funds advised by Clough Capital Partners LP. Based in Redwood City, Calif., ARMO BioSciences develops immunotherapies that treat cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases.
10 February 2016•4 mins read
